首页> 外文期刊>Therapeutic Drug Monitoring >New Mass Spectrometric Approaches for the Quantitative Evaluation of Anticancer Drug Levels in Treated Patients
【24h】

New Mass Spectrometric Approaches for the Quantitative Evaluation of Anticancer Drug Levels in Treated Patients

机译:治疗患者抗癌药物水平定量评估的新型质谱方法

获取原文
获取原文并翻译 | 示例
           

摘要

Alternatively to the well-consolidated liquid chromatography coupled to tandem mass spectrometry approach used for the evaluation of anticancer drug concentrations in treated patients, new mass spectrometric methods have been proposed and tested recently. They exhibited faster analysis time and, at first sight, simpler instrumental approaches. However, results obtained by these methods require an in-depth evaluation, because of their strong dependence on the experimental set-up. In this short review, the quantification of irinotecan, sunitinib, and 6-alpha-hydroxy paclitaxel (the main metabolite of paclitaxel) by laser desorption ionization techniques (matrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization, and surface-assisted laser desorption/ionization) is reported and discussed, showing the advantages but also the drawbacks of the methods. The matrix-assisted laser desorption/ionization approach led to the most reliable results, and the cross-validation for the quantitative analysis of irinotecan indicates that this method can be fruitfully used for therapeutic drug monitoring and pharmacokinetic studies. Another recently proposed technique, paper spray mass spectrometry, has been tested for the quantitative measurement of imatinib in plasma samples. Even if the approach is, at first sight, really simple, the parameterization of the analytical and instrumental aspects has required many efforts to reach satisfactory results. What it should be expected in the future is the evaluation of these methods, not only in scientific environments dedicated to instrument development, but also in clinical chemistry laboratories, to evaluate their effectiveness and to give new and valid tools for TDM and for other qualitative or quantitative measurements of biomedical interest.
机译:作为良好的溶液液相色谱,偶合至串联质谱法用于评估治疗患者中的抗癌药物浓度,最近提出并测试了新的质谱方法。它们展出了更快的分析时间,乍一看,略可简单的乐器方法。然而,通过这些方法获得的结果需要进行深入的评估,因为它们对实验设置的强依赖性。在本次要评审中,通过激光解吸电离技术(紫杉醇的主要代谢物)定量伊替替康,瑞科替尼,6-α-羟基吡啶(紫杉醇的主要代谢物)(基质辅助激光解吸/电离,纳米结构辅助激光解吸/电离和表面讨论和讨论了激光解吸/电离),展示了这些优点,也讨论了这些方法的缺点。矩阵辅助激光解吸/电离方法导致最可靠的结果,并且伊替康的定量分析的交叉验证表明该方法可以效果效果用于治疗药物监测和药代动力学研究。已经测试了另一种最近提出的技术,纸喷射质谱法已经过血浆样品中的伊马替尼的定量测量。即使这种方法是,一见钟情真的很简单,分析和乐器方面的参数化也需要许多努力达到满意的结果。在未来应该预期的是评估这些方法,不仅在科学环境中致力于仪器开发,而且在临床化学实验室,评估其有效性,并为TDM提供新的和有效的工具和其他定性或生物医学兴趣的定量测量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号